HomeRP • CVE
add
RepliCel Life Sciences Inc
Previous close
$0.055
Year range
$0.040 - $0.25
Market cap
3.58M CAD
P/E ratio
5.77
Dividend yield
-
Primary exchange
CVE
Market news
Financials
Income Statement
Revenue
Net income
| (CAD) | Sep 2023info | Y/Y change |
|---|---|---|
Revenue | 88.43K | 0.00% |
Operating expense | 413.92K | 51.86% |
Net income | -818.60K | 26.63% |
Net profit margin | -925.67 | 26.63% |
Earnings per share | — | — |
EBITDA | -325.48K | -76.96% |
Effective tax rate | — | — |
Balance Sheet
Total assets
Total liabilities
| (CAD) | Sep 2023info | Y/Y change |
|---|---|---|
Cash and short-term investments | 32.48K | -65.92% |
Total assets | 331.46K | -27.41% |
Total liabilities | 6.97M | -24.55% |
Total equity | -6.64M | — |
Shares outstanding | 65.00M | — |
Price to book | -0.55 | — |
Return on assets | -196.76% | — |
Return on capital | 14.67% | — |
Cash Flow
Net change in cash
| (CAD) | Sep 2023info | Y/Y change |
|---|---|---|
Net income | -818.60K | 26.63% |
Cash from operations | -200.29K | 48.81% |
Cash from investing | — | — |
Cash from financing | -1.00 | -100.00% |
Net change in cash | -200.29K | -50.94% |
Free cash flow | -236.98K | -443.09% |
About
RepliCel Life Sciences is a Canadian regenerative medicine company based in Vancouver, British Columbia. The company focuses on development of cell therapies using a patient's own cells. The company has treatment development activities targeting chronic tendon injuries which have failed to heal properly, and hair restoration. The company's expertise lies in isolation and exploitation of different cell populations found in the human hair follicle.
The company's business model is focused on establishing proof-of-concept for treatments leading to acquisition by a larger company. An alternative business model has been reported which does not involve acquisition but rather partnership where technologies and methods are licensed to a partner which will commercialize them. Wikipedia
Founded
1967
Headquarters
Website
Employees
1
